S

Sanofi

Global pharma company; vaccines and R&D

Expert Quality Services (Product Complaints) - Product Complaints

Full-TimeUpdated on 10/24/2026Deadline 11/6/26
No salary listed
Senior, Expert
Bachelor's, Master's
Hyderabad, Telangana, India
In Person
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • Six to ten years of related experience in the pharmaceutical industry.
  • Knowledge of current Good Manufacturing Practices, Code of Federal Regulations for drugs and biologics, complaint database software, and reporting tools.
  • Knowledge of quality functions in the pharmaceutical industry.
  • A Bachelor's or Master's degree in Life Sciences, Healthcare, or Pharmaceutical Science.
  • Excellent spoken and written English.
  • Problem-solving, attention to detail, organizational skills, analytical skills, and the ability to multitask in a stressful environment.
  • Ability to work in a team-oriented, flexible, and proactive manner.
Responsibilities
  • Handle Product Technical Complaints for medical devices, pharmaceutical products, biologics, and combination products in compliance with regulatory standards, collaborating with relevant internal and external stakeholders as applicable.
  • Enter complaints into the appropriate database, assess them, and process them promptly within the defined scope; participate in product-specific complaint meetings and provide timely feedback needed for investigations.
  • Complete required training on time and maintain knowledge through the annual training plan.
  • Ensure documentation and quality processes comply with applicable regulations and company standards; handle Quality Management System records while applying data privacy regulations, managing discrepancies, and meeting timelines.
  • Document Hub-related GxP activities and facilitate periodic governance meetings with stakeholders.
  • Participate in preparing presentations, Standard Operating Procedures, and training materials.
  • Download periodic reports from relevant systems to verify complaints are received and processed on time; perform quality checkpoints on complaint management activities and support audits and regulatory inspections.
  • Support continuous-improvement initiatives and projects involving standardization, simplification, and digitalization.
  • Create or review inquiries and translate them into English as applicable.
  • Determine whether inquiries concern adverse events, Pharmacovigilance special situations, customer service, or Field Alert Reporting, and communicate with the relevant teams when required.
  • Follow up with complainants for additional information and manage complaint samples as applicable; review and close non-Product Technical Complaint information appropriately, capture sample information in system fields, and complete required information.
  • Handle health-authority, prioritized, and suspected-counterfeit complaints urgently and in compliance with global and country-specific regulations.
  • Acknowledge complaints as applicable and communicate with complainants regarding requests or additional information.
  • Categorize Product Technical Complaints according to potential impact on product quality or patient safety within defined timelines; record complaint details in the global system, including defective quantity and lot number verification.
  • Categorize and process fast-track complaints using defined criteria; request sample collection and update sample or picture information in the global system.
  • Complete required system fields and assign complaints to the appropriate investigation-owning site; ensure investigations are completed, perform final review and updates, and close complaint records within defined timelines.
  • Provide an acknowledgement or response letter to the complainant as applicable, while maintaining compliance with regulatory requirements for complaint management and reporting.
Desired Qualifications
  • Experience working at manufacturing sites is an added advantage.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...